Abbott Park, Illinois | April 25, 2026

Abbott has unveiled late-breaking clinical data at the Heart Rhythm Society (HRS) 2026 Congress, demonstrating strong outcomes across its pulsed field ablation (PFA) and conduction system pacing (CSP) portfolios for treating abnormal heart rhythms, including atrial fibrillation (AFib). The data, derived from multiple clinical trials, highlight significant advancements in cardiac electrophysiology technologies, reinforcing Abbott’s position as a leader in next-generation cardiovascular MedTech innovation.

Dual-Energy Ablation Catheter Shows High Efficacy and Safety

One of the key highlights includes six-month results from the FlexPulse IDE study, evaluating the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ in patients with complex AFib. The results demonstrated that 87% of patients remained free from documented arrhythmias, while the device achieved an impressive 98.3% safety profile with no major adverse events.

The catheter’s dual-energy capability, combining radiofrequency (RF) and pulsed field ablation (PFA), allows physicians to tailor treatment strategies based on individual patient anatomy and disease complexity. Notably, 93.3% of patients were successfully treated using PFA alone, underscoring the growing importance of non-thermal ablation technologies in improving procedural precision and minimizing collateral tissue damage.

Additionally, procedural efficiency was high, with 93.9% of patients not requiring repeat ablation, reflecting the system’s ability to deliver durable and effective outcomes in a single intervention. These findings support ongoing efforts to secure U.S. FDA approval, following the device’s earlier CE Mark clearance in Europe.

Advertisement

cGxPJobs Banner

Next-Generation Pacing Technologies Demonstrate Promising Results

Abbott also presented data from two late-breaking studies focused on conduction system pacing (CSP) technologies, including the investigational UltiSynq™ CSP implantable cardioverter-defibrillator (ICD) lead and the AVEIR™ CSP leadless pacemaker system. These innovations are designed to replicate the heart’s natural electrical activation, improving physiological pacing compared to traditional approaches.

The ASCEND CSP IDE trial showed that the UltiSynq system achieved a 97.5% safety rate and 99% success in achieving left bundle branch area pacing, with 100% defibrillation success and stable electrical performance. Meanwhile, early results from the first-in-human LEAP2 study of the AVEIR leadless system demonstrated high implantation success rates and reliable device performance, indicating strong potential for minimally invasive cardiac rhythm management solutions.

These advancements reflect a broader shift toward physiological pacing techniques, which aim to improve long-term cardiac function and reduce complications associated with conventional pacing systems.

Volt PFA System Strengthens AFib Treatment Outcomes

Further reinforcing its leadership in PFA technology, Abbott presented six-month data from the Volt™ PFA System CE Mark Extension Cohort trial, demonstrating high safety with no reported complications and strong efficacy in treating AFib, particularly in posterior wall ablation procedures.

Physicians reported that the system’s intuitive design and ease of use contributed to efficient procedures with fewer energy applications, enhancing both clinical workflow and patient outcomes. The Volt system, which has already received FDA approval and CE Mark certification, represents a key component of Abbott’s expanding electrophysiology portfolio.

Collectively, these findings emphasize the importance of integrated cardiovascular solutions, where advanced ablation technologies and innovative pacing systems work together to address the complexities of heart rhythm disorders.

Driving the Future of Cardiac Electrophysiology

The comprehensive data presented by Abbott highlight a holistic approach to treating arrhythmias, combining precision ablation, physiologic pacing, and digital integration. As AFib continues to affect millions globally, the need for safe, effective, and scalable treatment options remains critical.

Abbott’s continued investment in clinical research and technology innovation underscores its commitment to improving patient outcomes and advancing cardiovascular care. By leveraging cutting-edge MedTech solutions, the company is helping to redefine treatment paradigms and enable physicians to deliver personalized, data-driven care.

As the field evolves, these advancements are expected to reduce recurrence rates, improve quality of life, and enhance long-term cardiac health, positioning Abbott at the forefront of next-generation electrophysiology and cardiac device innovation.

Source: Abbott press release